Levosimendan Amdipharm

Active Ingredient:: Levosimendan
Origin:: EU

Levosimendan Amdipharm (Levosimendan)

Q: What conditions is Levosimendan Amdipharm used to treat?

Levosimendan Amdipharm is indicated for acute decompensated heart failure and cardiogenic shock. It is used in hospital settings to improve cardiac output, reduce pulmonary congestion, and support systemic blood pressure in patients with severe cardiac dysfunction.

Q: How does levosimendan work in the body?

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that lowers afterload and improves overall circulation.

Q: What is the usual dose of Levosimendan Amdipharm?

The dosing regimen for Levosimendan Amdipharm is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual patient needs.

Q: Is Levosimendan safe to use during pregnancy or breastfeeding?

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

Q: How do I order Levosimendan Amdipharm from GNH India?

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Q: How does Levosimendan compare with other inotropes?

Unlike traditional inotropes that increase intracellular calcium, levosimendan sensitises the heart to existing calcium, reducing the risk of calcium‑overload toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that many other agents lack.

Q: What are the storage requirements for Levosimendan Amdipharm?

Levosimendan Amdipharm must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

Q: How is Levosimendan Amdipharm administered?

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a monitored setting, typically starting with a loading dose followed by a continuous infusion, as directed by the treating physician.

Q: What are the most serious risks associated with Levosimendan?

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout the infusion.

Q: Who should not receive Levosimendan Amdipharm?

Levosimendan is contraindicated in patients with baseline systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment.

Levosimendan, the active ingredient in Levosimendan Amdipharm, is a calcium sensitizer / inodilator presented as an injectable solution for intravenous use. It treats acute decompensated heart failure and cardiogenic shock in hospitalized patients.

GNH India supplies Levosimendan Amdipharm as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Manufacturer / TM Owner

Amdipharm Limited

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Levosimendan is used in the management of severe cardiac conditions where enhanced contractility and vasodilation are required.

Acute decompensated heart failure: improves cardiac output and relieves pulmonary congestion.
Cardiogenic shock: supports systemic blood pressure and organ perfusion.
Pre‑transplant stabilization: provides hemodynamic support while awaiting definitive therapy.

How It Works

Levosimendan binds to cardiac troponin C, increasing its sensitivity to calcium and thereby augmenting contractile force without raising intracellular calcium levels. Simultaneously, it opens ATP‑sensitive potassium channels in vascular smooth muscle, causing arterial and venous dilation that reduces cardiac afterload and improves systemic circulation.

Side Effects

Levosimendan may be associated with several adverse reactions that clinicians monitor during therapy.

Common Side Effects

Hypotension: reduction in systolic blood pressure.
Headache: mild to moderate intensity.
Nausea: occasional gastrointestinal upset.
Tachycardia: increased heart rate.
Arrhythmia: non‑sustained ventricular ectopy.

Serious or Rare Side Effects

Severe hypotension: may require vasopressor support.
Ventricular tachyarrhythmias: potentially life‑threatening.
Myocardial ischemia: chest pain or ECG changes.
Allergic reactions: rash, pruritus, or anaphylaxis.
Pulmonary edema: worsening respiratory status.
Liver enzyme elevation: transient transaminase rise.

Precautions & Warnings

Levosimendan requires careful monitoring and specific safety measures before and during administration.

Blood pressure monitoring: check for hypotension before infusion.
Cardiac rhythm surveillance: observe for arrhythmias during therapy.
Dose adjustment: consider renal or hepatic impairment when determining infusion rate.
Concomitant vasodilators: use cautiously with nitrates or other blood‑pressure‑lowering agents.
Severe hypotension: avoid in patients with baseline systolic pressure <90 mmHg.
Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Levosimendan can interact with other medicines that affect cardiovascular function or drug metabolism.

Major Interactions (Avoid)

Potent CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase levosimendan exposure.
Other inotropes or calcium sensitizers: risk of excessive cardiac stimulation.

Moderate Interactions (Monitor Closely)

Nitrates or other vasodilators: additive hypotensive effect.
Beta‑blockers: may blunt desired inotropic response.
Diuretics: monitor electrolyte balance and volume status.
Anticoagulants: watch for bleeding if hypotension occurs.
Anti‑arrhythmic agents: assess for synergistic rhythm disturbances.

Frequently Asked Questions

Levosimendan Amdipharm is indicated for acute decompensated heart failure and cardiogenic shock. It is used in hospital settings to improve cardiac output, reduce pulmonary congestion, and support systemic blood pressure in patients with severe cardiac dysfunction.

Levosimendan enhances the sensitivity of cardiac troponin C to calcium, which increases the strength of heart muscle contraction without raising intracellular calcium. It also opens ATP‑sensitive potassium channels in vascular smooth muscle, causing vasodilation that lowers afterload and improves overall circulation.

The dosing regimen for Levosimendan Amdipharm is determined by the prescribing clinician based on the patient’s clinical status, weight, and response. The prescriber sets the infusion rate and duration according to approved guidelines and individual patient needs.

Safety data for levosimendan in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Unlike traditional inotropes that increase intracellular calcium, levosimendan sensitises the heart to existing calcium, reducing the risk of calcium‑overload toxicity. It also provides vasodilation through potassium‑channel activation, offering a combined inotropic and afterload‑reducing effect that many other agents lack.

Levosimendan Amdipharm must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution to maintain stability.

The product is supplied as an injectable solution for intravenous infusion. Administration is performed by a qualified healthcare professional in a monitored setting, typically starting with a loading dose followed by a continuous infusion, as directed by the treating physician.

Serious risks include severe hypotension, ventricular arrhythmias, myocardial ischemia, and rare allergic reactions. Patients should be closely monitored for blood pressure, heart rhythm, and signs of ischemia throughout the infusion.

Levosimendan is contraindicated in patients with baseline systolic blood pressure below 90 mmHg, severe obstructive cardiomyopathy, or known hypersensitivity to the drug. Caution is also advised in individuals with significant renal or hepatic impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 28 Aug 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.